Research programme: allergy vaccines - Allergy Therapeutics

Drug Profile

Research programme: allergy vaccines - Allergy Therapeutics

Alternative Names: Broad-spectrum grass allergoid vaccine - Allergy Therapeutics; Lol p1 vaccine - Allergy Therapeutics; Polyvac Peanut

Latest Information Update: 20 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Allergy Therapeutics
  • Class Allergy immunotherapies; Virus-like particle vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Food hypersensitivity
  • Research Grass pollen hypersensitivity

Most Recent Events

  • 07 Mar 2018 Allergy Therapeutics plans a first-in-human phase I trial for Food (Peanut) allergy in 2019
  • 12 Dec 2017 Ergomed and Allergy Therapeutics agree to co-develop allergy vaccines in United Kingdom for house dust mite, tree pollen and grass pollen
  • 03 Mar 2017 Early research in Grass pollen hypersensitivity in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top